ICOS binding proteins
The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO: 1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
1. A method of treating cancer in a human in need thereof, the method comprising administering an anti-ICOS agonist antibody or antigen binding portion thereof to said human, wherein the anti-ICOS agonist antibody binds to human ICOS and has reduced antibody dependent cell mediated cytotoxicity (ADCC) activity compared to ADCC activity of an IgG 1 control antibody.
2. The method of claim 1 , wherein the anti-ICOS agonist antibody comprises a mutated IgG1 constant region.
3. The method of claim 1 , wherein the anti-ICOS agonist antibody has reduced affinity for an Fc receptor compared to affinity of an IgG1 control antibody for the Fc receptor.
4. The method of claim 1 , wherein the IgG1 control antibody is wildtype (WT) IgG1.
5. The method of claim 3 , wherein the IgG1 control antibody is wildtype (WT) IgG1.
6. The method of claim 3 , wherein the Fc receptor is CD16.
7. The method of claim 1 , wherein the anti-ICOS agonist antibody is a monoclonal antibody.
8. The method of claim 1 , wherein the anti-ICOS agonist antibody is humanized.
9. The method of claim 1 , wherein the anti-ICOS agonist antibody is fully human.
10. The method of claim 1 , wherein the cancer is a solid tumor.
11. The method of claim 1 , wherein the cancer is selected from: colorectal cancer (CRC), esophageal cancer, cervical cancer, bladder cancer, breast cancer, head and neck cancer, ovarian cancer, melanoma, renal cell carcinoma, EC squamous cell, non-small cell lung carcinoma, mesothelioma, prostate cancer, and gastric cancer.
12. The method of claim 1 , further comprising administering to said human an anti-PD-1 antibody or antigen binding portion thereof, an anti-PD-L1 antibody or antigen binding portion thereof, an anti-CTLA4 antibody or antigen binding portion thereof, or a chemotherapeutic agent.
13. The method of claim 12 , wherein the anti-PD-1 antibody is nivolumab.
14. The method of claim 12 , wherein the anti-PD-1 antibody is pembrolizumab.
15. The method of claim 12 , wherein the anti-CTLA4 antibody is ipilimumab.
16. The method of claim 12 , wherein the chemotherapeutic agent is an alkylating agent, antimetabolite, antibiotic, topoisomerase inhibitor, anti-mitotic agent, hormone, or hormone analog.
17. The method of claim 12 , wherein the chemotherapeutic agent is selected from: paclitaxel, docetaxel, gemcitabine, carboplatin, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, melphalan, 5-fluorouracil, mercaptopurine, floxuridine, fludarabine, hydroxyurea, methotrexate, daunorubicin, doxorubicin, actinomycin, bleomycin, topotecan, irinotecan, etoposide, teniposide, vinblastine, vincristine, vinorelbine, prednisone, and prednisolone.
18. The method of claim 11 , wherein the cancer is selected from colorectal cancer (CRC), esophageal cancer, cervical cancer, bladder cancer, breast cancer, head and neck cancer, melanoma, and non-small cell lung carcinoma.